Delivery Order SPE2DB24D2205-SPE2DB25FEABD

Award Date 3/25/25
Potential Completion Date 4/15/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,526.54 firm fixed-price delivery order is for the supply of the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract has an ultimate completion date of April 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $1,263.27 and is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025 and is a firm fixed price delivery order. This award is not designated as a set-aside contract. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The firm-fixed-price delivery order has a ceiling value of $1,263.27 and a period of performance through June 10, 2025. The contract is not set aside for a specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,571.06 delivery order contract is for the supply of Hemangeol 4.28 mg/ml oral solution. The contract has a firm fixed price pricing type and a completion date of December 10, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $2,526.54, is for the delivery of the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract is a Firm Fixed Price Delivery Order with a completion date of January 28, 2025. This award is not associated with a set-aside program. AmerisourceBergen Drug Corp has an...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The $1,684.36 contract has a period of performance through July 29, 2025. This award is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global...
This federal contract award is for the pharmaceutical product HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,105.45 firm fixed price delivery order contract was awarded by the Defense Logistics Agency, a defense agency, on July 3, 2025 with a completion date of July 25, 2025. The contract is not set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, under contract ID SPE2DB20D1100|SPE2DB25FA3W4. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $3,368.72 and a period of performance through February 24, 2025. The contract was awarded on January 31,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract has a ceiling value of $1,684.36 and a period of performance through June 3, 2025. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical supplier of medical and pharmaceutical products to federal agencies, including the Defense...
This is a Delivery Order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract has a ceiling value of $1,263.27 and is a Firm Fixed Price contract type. It is not a set-aside contract. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00, which provides a...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FEABD
    Delivery Order

This federal contract award, valued at $1,684.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 15, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific contract award is not designated as a set-aside.

Generated 6/24/25, 9:58 AM